On Tuesday,Shares of AbbVie Inc (NYSE:ABBV), SUBTRACT -0.36% and closed at $63.00 in the last trading session. The last trading range of the stock ranges between $62.55 and $63.53. AbbVie (ABBV), a global biopharmaceutical company, recently declared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed previous therapy with direct-acting antivirals (DAAs) in genotype 1 (GT1), counting therapy with an NS5A inhibitor and/or protease inhibitor.
The BTD is supported by positive results seen in AbbVie’s Phase 2 MAGELLAN-1 clinical study. According to the FDA, BTD is intended to expedite the development and review of therapies for serious or life threatening conditions.
“AbbVie is committed to advancing HCV care and addressing areas of continued unmet need for people living with chronic HCV,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “The FDA’s Breakthrough Therapy Designation is an important step in our effort to bring our pan-genotypic regimen to market, which we are also investigating as an eight week path to virologic cure for the majority of patients.”
Valeant Pharmaceuticals Intl Inc (NYSE:VRX), DROPPED -2.74% and closed at $23.74 in the last trading session. The last trading range of the stock ranges between $23.65 and $24.89. The company’s Market capitalization is $8.05 Billion with the total Outstanding Shares of 341.19 million. Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) declares its (unaudited) financial report for the eight months ended 31 August 2016. These financial statements are being published to provide all shareholders and shareholders with the most current financial information in order to facilitate a full understanding of the implications of the Company’s recently declared deal to acquire the commercialization rights to RUCONEST® in North America from its partner Valeant and the related projected financing activity.
These results do not replace the quarterly report for the first nine months of 2016, which is because of be published on 27 October 2016.
FirstEnergy Corp. (NYSE:FE), LOST -2.07% and closed at $31.63 in the last trading session. The last trading range of the stock ranges between $31.41 and $32.42. During the 52-week trading session the minimum price at which share price traded, registered at $28.89 and reached to max level of $36.60. FirstEnergy Corp. (FE) recently declared a Request for Proposal (RFP) to purchase both Ohio-compliant Solar Renewable Energy Credits (SRECs) and Renewable Energy Credits (RECs) for its Ohio utilities – Ohio Edison, Cleveland Electric Illuminating and Toledo Edison. The purchases will assist meet the Companies’ 2016 renewable energy targets established under Ohio’s alternative energy law.
SRECs and RECs sought in this RFP must be able to be utilized by the Companies for compliance with its 2016 renewable energy obligations in accordance with rules and procedures put forth by the Public Utilities Commission of Ohio (PUCO), be deliverable through PJM-EIS GATS, and generated between January 1, 2014, and December 31, 2016. The following amounts are being sought: